Does Calibrate Replace My Primary Care Provider?

What Calibrate Actually Is

Calibrate is a telehealth program built around GLP-1 receptor agonist therapy combined with structured lifestyle coaching. It is not a comprehensive medical practice, a primary care clinic, or an urgent care center. The program runs for 12 months and assigns members to a board-certified obesity medicine physician for medication management and to lifestyle coaches for behavioral support.

The distinction matters clinically. Calibrate operates within a narrow, well-defined scope: prescribe and adjust GLP-1 medications, monitor metabolic markers relevant to those medications, and coach lifestyle change. Everything outside that scope still belongs to your PCP.

What the Calibrate Physician Does

The physician on the Calibrate side reviews your intake questionnaire, orders a baseline metabolic panel, assesses eligibility for GLP-1 therapy, writes the prescription, and performs periodic medication check-ins. Those check-ins are typically conducted asynchronously or through short video visits. The physician can adjust your dose, address medication side effects such as nausea or constipation, and flag concerns that require outside evaluation.

That last point is significant. If the Calibrate physician notices something outside their scope, they refer you back to your PCP. They do not take over management of that finding.

What the Calibrate Coaches Do

Coaches cover four behavioral domains Calibrate calls "Food, Sleep, Exercise, and Emotional Health." Sessions are conducted via video. Coaches are not licensed physicians, nurse practitioners, or registered dietitians, though Calibrate does employ registered dietitians in a consulting capacity depending on plan tier. Coaches cannot diagnose conditions, interpret labs in a clinical sense, or prescribe anything.

What Calibrate Does Not Provide

• Annual wellness exams or preventive screenings (mammography, colonoscopy, Pap smear)
• Management of comorbidities such as hypertension, hypothyroidism, or type 2 diabetes beyond the metabolic effects of GLP-1 therapy
• Mental health therapy or psychiatric medication management
• Emergency or urgent care
• Specialist referrals for cardiology, endocrinology, nephrology, or any other specialty
• Continuous, longitudinal care after the 12-month program ends (unless membership is renewed)

Why a Primary Care Provider Remains Essential

Your PCP holds longitudinal knowledge of your full medical history, manages your chronic conditions, coordinates specialist care, performs or orders preventive screenings, and serves as the first contact for acute illness. None of those functions transfer to Calibrate when you enroll.

The American Academy of Family Physicians defines primary care as "the provision of integrated, accessible health care services by clinicians who are accountable for addressing a large majority of personal health care needs, developing a sustained partnership with patients, and practicing in the context of family and community." Calibrate, by design, addresses only a subset of those needs.

Chronic Disease Management

GLP-1 receptor agonists can lower HbA1c, reduce blood pressure, and produce weight loss that improves multiple comorbidities. But the downstream management of those comorbidities still requires a physician who holds the full picture. If semaglutide reduces your HbA1c from 8.2% to 6.4%, your PCP needs to know so they can adjust your metformin or sulfonylurea dose. If you do not communicate that change, you risk hypoglycemia.

The American Diabetes Association's Standards of Care in Diabetes, 2024 explicitly recommends ongoing collaboration among prescribers when GLP-1 agents are added to an existing diabetes medication regimen. Calibrate does not have visibility into every medication your PCP prescribes. That communication gap is your responsibility to close.

Preventive Screenings

The U.S. Preventive Services Task Force recommends colorectal cancer screening beginning at age 45, breast cancer screening for women aged 40 to 74, and blood pressure measurement at every routine visit, among other Grade A and B recommendations. Calibrate does not fulfill any of these. Missing a screening because you assumed your Calibrate physician covered it could have serious consequences.

Medication Interactions and Polypharmacy

GLP-1 receptor agonists slow gastric emptying. This pharmacokinetic effect can reduce the absorption rate of oral medications taken concomitantly. A 2023 review in JAMA Internal Medicine examined cases in which delayed gastric emptying from GLP-1 therapy altered the absorption of cyclosporine, levothyroxine, and hormonal contraceptives. Your PCP, who manages your full medication list, is the appropriate clinician to evaluate and monitor those interactions. The Calibrate physician sees only a partial medication picture at enrollment.

How GLP-1 Therapy Works, and Why the Prescriber Scope Is Limited

Semaglutide and liraglutide are GLP-1 receptor agonists approved by the FDA for chronic weight management. Wegovy (semaglutide 2.4 mg weekly) received FDA approval for weight management in adults in June 2021. Saxenda (liraglutide 3.0 mg daily) received approval in 2014.

The clinical evidence for these drugs is substantial. In the STEP-1 trial (N = 1,961), semaglutide 2.4 mg produced a mean weight loss of 14.9% at 68 weeks compared with 2.4% in the placebo group (P<0.001) [1]. The SELECT trial (N = 17,604) showed that semaglutide 2.4 mg reduced major adverse cardiovascular events by 20% in adults with overweight or obesity and established cardiovascular disease, without diabetes [2].

Why Prescribing These Drugs Requires Context

Both drugs have contraindications and precautions that require a complete medical picture. GLP-1 agonists are contraindicated in patients with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 [3]. Pancreatitis has been reported with GLP-1 use. Gallbladder disease is more common in patients losing weight rapidly on these agents. Monitoring these risks across a 12-month program requires clinical follow-up that extends beyond medication titration, which is why Calibrate's model relies on members maintaining their PCP relationship.

Dose Titration and Side Effect Management

Calibrate physicians titrate semaglutide or liraglutide over several weeks using a standard protocol. For semaglutide, the typical titration begins at 0.25 mg weekly for four weeks, then advances at four-week intervals to 0.5 mg, 1 mg, 1.7 mg, and finally 2.4 mg. Gastrointestinal side effects (nausea, vomiting, diarrhea) peak during the up-titration phase. Calibrate coaches help members manage these symptoms behaviorally. For severe or persistent symptoms, the Calibrate physician may adjust the schedule or pause titration. If a symptom pattern suggests something beyond typical GI intolerance, such as epigastric pain radiating to the back, you need your PCP or an emergency department, not a coaching session.

What Calibrate's Own Policies Say

Calibrate's member materials state explicitly that the program is not intended to replace a member's primary care provider. Their intake process asks members to disclose current medications and existing conditions, but Calibrate does not contact your PCP on your behalf or transmit records to your PCP's electronic health record unless you specifically arrange for that.

This creates a practical coordination gap. Below is a framework for managing that gap:

The HealthRX Calibrate-PCP Coordination Checklist

1. Before starting Calibrate: Tell your PCP you are enrolling. Share the name of the GLP-1 medication you will be prescribed and the starting dose.
2. At every PCP visit during the program: Bring your current Calibrate medication summary. Update your PCP on your current dose, any side effects, and your most recent Calibrate lab results.
3. If your HbA1c, blood pressure, or lipid panel changes significantly: Request that your PCP review whether any of your existing medications need dose adjustment.
4. If you experience new symptoms during the program: Contact your PCP first for anything that could be a new or worsening medical condition. Contact Calibrate support for medication side effects you believe are GLP-1-related.
5. At the end of the 12-month program: Ask your PCP to review your updated metabolic panel and body weight, and discuss a maintenance plan before your Calibrate membership lapses.

Calibrate's Clinical Evidence and Published Outcomes

Calibrate has published internal member outcome data showing an average of 15% body weight loss at 12 months across their program population. This figure aligns directionally with STEP-1 trial results for semaglutide, though program-level data should be interpreted with caution since it lacks the randomization and placebo control of an RCT.

The broader evidence base for combining GLP-1 pharmacotherapy with lifestyle intervention is strong. A 2021 Cochrane review of liraglutide for weight management [4] found that liraglutide 3.0 mg produced 5.4 kg greater weight loss than placebo over 56 weeks when combined with diet and exercise counseling. Programs that pair medication with structured behavioral coaching consistently outperform medication alone in sustaining weight loss, which is the structural premise behind Calibrate's model.

The Endocrine Society's Clinical Practice Guideline on Obesity Pharmacotherapy states: "We recommend adjunctive pharmacotherapy for patients with obesity who have not achieved clinically meaningful weight loss (5% or more of initial body weight) with lifestyle intervention alone." That guideline also makes clear that pharmacotherapy should be accompanied by, not substituted for, ongoing medical care.

Who Is Eligible for Calibrate

Calibrate accepts adults with:

• BMI of 30 or higher, or
• BMI of 27 or higher plus at least one weight-related condition (type 2 diabetes, hypertension, dyslipidemia, obstructive sleep apnea)

These eligibility criteria mirror the FDA-labeled indications for semaglutide 2.4 mg (Wegovy) [3]. Calibrate does not accept members with a history of medullary thyroid carcinoma, MEN2, pancreatitis, or eating disorders, which are contraindications to GLP-1 therapy.

Lab Requirements

Calibrate requires a baseline metabolic panel before initiating medication. This typically includes HbA1c, fasting glucose, a comprehensive metabolic panel, and a lipid panel. These labs are ordered through Calibrate's partner laboratory. Your PCP does not automatically receive the results. You need to share them yourself, or authorize release.

Telehealth Weight Loss Programs vs. Traditional Primary Care: Understanding the Difference

Telehealth weight-loss programs such as Calibrate, Found, Sequence, and Ro Body operate in a space that did not exist at meaningful scale before 2020. The COVID-19 pandemic accelerated telehealth adoption, and the DEA's temporary rules allowing GLP-1 prescribing via telemedicine without an in-person visit extended that access [5].

These programs serve a real need. Access to obesity medicine specialists is limited. A 2023 analysis estimated fewer than 7,000 board-certified obesity medicine physicians practice in the United States, serving a population in which roughly 42% of adults have obesity, per CDC data [6]. Telehealth programs scale GLP-1 access in ways that traditional clinic-based care cannot.

The tradeoff is scope. No telehealth weight-loss program currently provides the continuity and breadth of a primary care relationship. They were not designed to. The appropriate mental model is specialty-adjacent care, not primary care replacement.

How Calibrate Compares to an Obesity Medicine Clinic

An outpatient obesity medicine clinic typically offers in-person visits, direct EHR integration with your PCP's system (if using a shared network), referral pathways to endocrinology or bariatric surgery, and the ability to manage comorbidities or at least communicate directly with the physicians who do. Calibrate offers greater convenience and lower cost per visit, but with reduced care integration.

Patients who have complex metabolic disease, multiple comorbidities, or prior bariatric surgery may be better served by an in-person obesity medicine specialist than by a telehealth-only program. Your PCP can help you make that determination.

Medication Continuity After Calibrate

One underappreciated issue: what happens to your GLP-1 prescription when your Calibrate membership ends? Calibrate does not automatically transfer your prescription to your PCP. If you want to continue semaglutide after the 12-month program, you need a prescriber who will take over. Discuss this with your PCP at least 60 to 90 days before your Calibrate membership lapses. Some PCPs are comfortable continuing GLP-1 therapy; others prefer to refer you to an endocrinologist or obesity medicine specialist. Knowing your PCP's comfort level in advance prevents a gap in medication supply, which can lead to weight regain.

Research from the STEP-4 withdrawal trial (N = 803) showed that participants who discontinued semaglutide 2.4 mg after 20 weeks regained, on average, two-thirds of their prior weight loss within 48 weeks [7]. Continuity of the prescription matters.

Practical Steps for Calibrate Members

If you are currently enrolled in Calibrate or considering enrollment, these steps help ensure your medical care remains coherent:

Step 1. Inform your PCP before your first Calibrate physician visit. Bring your Calibrate intake summary to your next PCP appointment.

Step 2. Share your Calibrate lab results with your PCP within two weeks of receiving them. Do not assume the two systems communicate.

Step 3. Keep a single medication list that includes all prescriptions from both your PCP and Calibrate. Bring it to every appointment with either provider.

Step 4. If your blood pressure drops meaningfully during the program (common with significant weight loss), contact your PCP. Your antihypertensive doses may need reduction.

Step 5. Schedule a dedicated coordination visit with your PCP at the six-month mark and again at the end of the 12-month program.

Step 6. Plan your post-program prescribing continuity at least 60 days before your membership ends.